-
Review Article
-
J Mult Scler. 2016;7(2):49-54. Published online September 1, 2016.
- 다발성경화증에서 알렘투주맙 치료
-
오지영
-
건국대학교병원
-
- Alemtuzumab in the Treatment of Multiple Sclerosis
-
Jeeyoung Oh
-
Department of Neurology, Konkuk University Medical Center, Seoul, Korea
-
- Abstract
- "Alemtuzumab is a humanized monoclonal antibody against CD52 and is recently approved for the second-line therapy of active relapse-remitting multiple sclerosis in Korea. Alemtuzumab leads to arapid and long-lasting depletion of peripheral T and B cells with repopulation of immune cell compositionresulting in the rebalancing of immune-tolerance network. However, it has a considerable adverseeffects including infusion associated reaction, infection, and secondary autoimmune diseaserequiring close and regular monitoring during and for 4 years after the final infusion cycle. This reviewwill provide a summary of mechanism of action, data from the pivotal clinical studies, and safetyprofiles of alemtuzumab. Journal of Multiple Sclerosis 7(2):49-54, 2016"
Keywords :Alemtuzumab, CD52, Monoclonal antibody, Multiple sclerosis
